21 recruiting, 13 active not recruiting, 7 completed, 6 terminated. 35 Phase 2, 16 Phase 1, 6 Phase 3, 2 Not applicable, 1 Phase 4.
Follow Recurrent Head and Neck Squamous Cell Carcinoma: new trials by email Literature Review of Recurrent Head and Neck Squamous Cell Carcinoma trials Research Report on Recurrent Head and Neck Squamous Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma Biospecimen Collection, Camonsertib, Computed Tomography - Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Recurrent Head and Neck Squamous Cell Carcinoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 39 | 2027-02-13 | 2026-09-03 |
| A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC Ficerafusp alfa, Pembrolizumab (KEYTRUDA®) - Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | Phase 2 | Recruiting | Bicara Therapeutics | 160 | 2026-09-01 | 2026-10-13 |
| Anti-PD-1 Therapy in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma Neoadjuvant PD-1 antibody plus chemotherapy, surgery, Adjuvant PD-1 antibody - Recurrent Head and Neck Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Yanjie Zhang, MD | 217 | 2026-08-01 | 2026-08-07 |
| Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Biopsy Procedure, Biospecimen Collection - Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 44 | 2026-05-27 | 2026-10-16 |
| Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study Biospecimen Collection, Immune Checkpoint Inhibitor - Advanced Biliary Tract Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma | Phase 4 | Recruiting | OHSU Knight Cancer Institute | 160 | 2026-04-24 | 2026-10-13 |
| BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent HNSCC After Immunotherapy Progression Finotonlimab, Cetuximab, Docetaxel - Recurrent Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer | Phase 2 | Enrolling by invitation | Sun Yat-sen University | 42 | 2026-04-20 | 2026-06-01 |
| Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC radiotherapy, Cisplatin, Pembrolizumab - Recurrent Head and Neck Squamous Cell Carcinoma | Phase 3 | Recruiting | Universität des Saarlandes | 214 | 2025-10-30 | 2026-09-10 |
| Phase I/ II Trial Combining PD-1 Inhibition and Neoadjuvant Proton or Photon Radiation Therapy in Recurrent Head and Neck Squamous Cell Carcinoma Proton therapy, Pembrolizumab - Head and Neck Cancer, Recurrent Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | University of Cincinnati | 40 | 2025-10-08 | 2026-07-01 |
| Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation Audiometric Test, Interview - Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Cutaneous Squamous Cell Carcinoma of the Head and Neck | Not applicable | Recruiting | Emory University | 118 | 2025-08-25 | 2026-07-16 |
| TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer Autologous Tumor Membrane Vesicles Vaccine, Biospecimen Collection, Computed Tomography - Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma | Phase 1 | Recruiting | Emory University | 40 | 2025-05-08 | 2026-03-04 |
| Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment Biospecimen Collection, Cetuximab, Computed Tomography - Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma | Phase 3 | Recruiting | National Cancer Institute (NCI) | 158 | 2025-03-27 | 2026-10-19 |
| FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC Ficerafusp alfa, Pembrolizumab (KEYTRUDA®), Placebo - Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | Phase 2 / Phase 3 | Recruiting | Bicara Therapeutics | 650 | 2025-01-28 | 2026-10-02 |
| Establishment of a Microfluidic Based Liquid Biopsy Platform for Recurrent/Metastatic Head and Neck Cancers Prognostication Using NK Cell IFN-γ Expression and CTM Correlation With DS-SACA Chip Head and Neck Cancers- Squamous Cell, Head and Neck Cancer Metastatic | Recruiting | National Taiwan University Hospital | 30 | 2025-01-01 | 2026-02-24 | |
| A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases ASP-1929 Photoimmunotherapy, Pembrolizumab, Carboplatin - Recurrent Head and Neck Squamous Cell Carcinoma | Phase 3 | Recruiting | Rakuten Medical, Inc. | 412 | 2024-12-24 | 2025-10-15 |
| Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial Biospecimen Collection, Computed Tomography, Lovastatin - Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Neck Squamous Cell Carcinoma of Unknown Primary | Phase 2 | Recruiting | Emory University | 28 | 2024-12-09 | 2026-02-11 |
| Identification of Pattern and Factors Affecting Recurrence in Head and Neck Carcinoma Recurrent Head and Neck Squamous Cell Carcinoma | Unknown | Sohag University | 35 | 2024-07-15 | 2024-06-25 | |
| Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program Home Health Encounter, Nivolumab, Patient Monitoring - Advanced Esophageal Squamous Cell Carcinoma, Advanced Renal Cell Carcinoma | Phase 2 | Recruiting | Mayo Clinic | 50 | 2024-04-30 | 2026-10-02 |
| PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC PD-L1 t-haNK, Cetuximab, NAI - Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma | Phase 2 | Recruiting | Dana-Farber Cancer Institute | 25 | 2024-02-16 | 2026-10-19 |
| Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN RP3, CCRT(concurrent chemoradiation therapy), carboplatin and paclitaxel - Squamous Cell Carcinoma of Head and Neck, Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 2 | Withdrawn | Replimune, Inc. | 2024-01-30 | 2025-03-11 | |
| A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma Ficlatuzumab, Cetuximab, Placebo - Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | Phase 3 | Recruiting | AVEO Pharmaceuticals, Inc. | 410 | 2024-01-11 | 2026-04-09 |
Showing 20 of 53. Sign in to see all of them.
Squamous Cell Carcinoma of Head and Neck (53) · Head and Neck Neoplasms (11) · Mouth Neoplasms (11) · Carcinoma (10) · Laryngeal Neoplasms (10) · Hypopharyngeal Neoplasms (9) · Oropharyngeal Neoplasms (8) · Carcinoma, Non-Small-Cell Lung (5) · Nasopharyngeal Carcinoma (5) · Carcinoma, Squamous Cell (4) · Melanoma (4) · Neoplasm Metastasis (4) · Carcinoma, Renal Cell (3) · Lung Neoplasms (3) · Lymphoid Interstitial Pneumonia (3)
Neoplasms (53) · Neoplasms by Histologic Type (53) · Neoplasms by Site (53) · Neoplasms, Glandular and Epithelial (53) · Carcinoma, Squamous Cell (49) · Carcinoma (43) · Head and Neck Neoplasms (42) · Respiratory Tract Diseases (17) · Respiratory Tract Neoplasms (15) · Otorhinolaryngologic Diseases (13) · Mouth Diseases (11) · Otorhinolaryngologic Neoplasms (11) · Pharyngeal Diseases (11) · Pharyngeal Neoplasms (11) · Stomatognathic Diseases (11)
pembrolizumab (24) · Cetuximab (10) · Carboplatin (9) · Specimen Handling (9) · Magnetic Resonance Spectroscopy (8) · Cisplatin (6) · Radiosurgery (6) · Docetaxel (5) · Nivolumab (5) · Paclitaxel (4) · (225)Ac-DOTA-c(RGDyK) (3) · Radiotherapy, Intensity-Modulated (3) · Surgical Procedures, Operative (3) · cemiplimab (3) · 1,2-diaminocyclohexaneplatinum II citrate (2)
National Cancer Institute (NCI) (8) · Emory University (5) · M.D. Anderson Cancer Center (4) · Dana-Farber Cancer Institute (3) · Wake Forest University Health Sciences (3) · Bicara Therapeutics (2) · Mayo Clinic (2) · Rakuten Medical, Inc. (2) · Vanderbilt-Ingram Cancer Center (2) · Washington University School of Medicine (2) · AVEO Pharmaceuticals, Inc. (1) · Chase Heaton, MD (1) · Hyunseok Kang, MD (1) · Incyte Biosciences International Sàrl (1) · Marcelo Bonomi (1)
United States (45) · Taiwan (5) · France (4) · Germany (4) · United Kingdom (4) · Australia (3) · Canada (3) · Czechia (3) · Poland (3) · South Korea (3) · Spain (3) · Belgium (2) · China (2) · Greece (2) · Italy (2)
Eben Rosenthal, MD (2) · Mercedes Porosnicu, MD (2) · Nabil F. Saba, MD (2) · Yvonne M Mowery (2) · Aarti Bhatia (1) · Biren Saraiya (1) · Chandylen Nightingale (1) · Chase Heaton, MD (1) · Chenping Zhang, M.D. (1) · Chunyan Chen, MD, PhD (1) · Cristina P. Rodriguez (1) · Dan P Zandberg (1) · David Cohan, MD/FACS (1) · Dong M. Shin, MD, FACP, FAAAS (1) · Douglas Adkins, M.D. (1)
PMID 33720067, PMID 35575280, PMID 35780243, PMID 36977289, PMID 37012550, PMID 37199326, PMID 37875771, PMID 38249330, PMID 38780927, PMID 39462179, PMID 39948608, PMID 40852760, PMID 41498537, PMID 42313403
P30CA138292 (5), P30CA012197 (3), U10CA180820 (2), UM1CA186690 (2), K24DC022077 (1), N01CM00070 (1), P30CA015704 (1), P30CA016058 (1), P30CA023074 (1), P30CA072720 (1), R01CA262123 (1), R01CA266233 (1), R03CA208560 (1), U01CA076576 (1), U10CA180821 (1)